
CLAIMS

1. The compound of formula (I):



(I)

which may be in the form of an anhydrous base, a hydrate or a solvate,
for its use for the treatment of pediatric cancers.

2. The compound for the use of claim 1, for the treatment of pediatric solid tumors.

3. The compound for the use of claim 2, wherein the pediatric solid tumors are chosen from the group consisting of: anaplastic astrocytomas, glioblastomas, anaplastic oligodendrogliomas, oligoastrocytomas, anaplastic ependymomas, nephroblastoma, medulloblastomas, neuroblastomas, Wilm's tumors, rhabdomyosarcomas, chondrosarcomas, Ewing's sarcomas and osteosarcomas.

4. The compound for the use of any one of claims 1 to 3, for the treatment of rhabdomyosarcoma.

5. The compound for the use of any one of claims 1 to 3, for the treatment of Ewing's tumor.

6. The compound for the use of any one of claims 1 to 3, for the treatment of osteosarcoma.

7. The compound for the use of claim 1, for the treatment of high grade gliomas.

8. The compound for the use of any one of claims 1 to 7, wherein said compound is in the form of an acetone solvate.


9. The compound for the use of claim 8, wherein the acetone solvate comprises from 5% to 8% by weight of acetone.

10. The compound for the use of any one of claims 1 to 9, wherein said compound is administered by parenteral route.

11. The compound for the use of claim 10, wherein said compound is administered by intravenous route.

CLAIMS

1. The use of a compound of formula (I):



(I)

which may be in the form of an anhydrous base, a hydrate or a solvate,
for the preparation of a medicament for the treatment of pediatric cancers.

2. The use of claim 1, for the treatment of pediatric solid tumors.

3. The use of claim 2, wherein the pediatric solid tumors are chosen from the group consisting of: anaplastic astrocytomas, glioblastomas, anaplastic oligodendrogliomas, oligoastrocytomas, anaplastic ependymomas, nephroblastoma, medulloblastomas, neuroblastomas, Wilm's tumors, rhabdomyosarcomas, chondrosarcomas, Ewing's sarcomas and osteosarcomas.

4. The use of any one of claims 1 to 3, for the treatment of rhabdomyosarcoma.

5. The use of any one of claims 1 to 3, for the treatment of Ewing's tumor.

6. The use of any one of claims 1 to 3, for the treatment of osteosarcoma.

7. The use of claim 1, for the treatment of high grade gliomas.

8. The use of any one of claims 1 to 7, wherein the compound is in the form of an acetone solvate.

9. The use of claim 8, wherein the acetone solvate comprises from 5% to 8% by weight of acetone.

10. The use of any one of claims 1 to 9, wherein the compound is administered by parenteral route.

11. The use of claim 10, wherein the compound is administered by intravenous route.